Orforglipron Side Effects: What Studies and Users Report
What FDA labels, clinical studies and people who use Orforglipron report, how strong that evidence is, and what is still unknown.
Side effects reported in studies
Adverse reactions from the FDA label come first, then side effects reported in individual studies. Frequencies are quoted as the source gives them; animal results are labelled.
| Side effect | How common | Study type | Source |
|---|---|---|---|
| Most common adverse reactions (5% or more) | 5% or more of patients | FDA label | FDA label (Foundayo) |
| Nausea (placebo, 5.5 mg, 9 mg, 17.2 mg) | placebo 10%; 5.5 mg 26%; 9 mg 34%; 17.2 mg 35% | FDA label | FDA label (Foundayo) |
| Vomiting (placebo, 5.5 mg, 9 mg, 17.2 mg) | placebo 4%; 5.5 mg 13%; 9 mg 21%; 17.2 mg 24% | FDA label | FDA label (Foundayo) |
| Gastrointestinal events and discontinuation | 59% and 58% (orforglipron) vs 37% and 45% (oral semaglutide) | Human controlled trialn = 1698 | Lancet 2026, PMID 41765029 |
| Gastrointestinal events | 47%, 46%, 54% (3, 12, 36 mg) vs 12% dapagliflozin | Human controlled trialn = 962 | Lancet 2026, PMID 42259339 |
| Gastrointestinal events | most common | Human RCTn = 376 | Nature medicine 2026, PMID 42120723 |
| Gastrointestinal events | most common | Human RCTn = 616 | Obesity pillars 2026, PMID 42577069 |
| Gastrointestinal events | most common | Human RCTn = 3127 | The New England journal of medicine 2025, PMID 40960239 |
| Severe hypoglycemia | none reported | Human RCTn = 559 | The New England journal of medicine 2025, PMID 40544435 |
| Gastrointestinal events | discontinuation in 10 to 17% of participants | Human RCTn = 272 | The New England journal of medicine 2023, PMID 37351564 |
| Gastrointestinal events | 44·1% to 70·4% (orforglipron) vs 18·2% (placebo) | Human RCTn = 383 | Lancet 2023, PMID 37369232 |
| Gastrointestinal events | most common | Human RCTn = 92 | Diabetes, obesity & metabolism 2023, PMID 37344954 |
| Gastrointestinal events | most common | Human RCTn = 68 | Diabetes, obesity & metabolism 2023, PMID 37264711 |
| Gastrointestinal events | most common | Meta-analysisn = 815 | Archives of endocrinology and metabolism 2024, PMID 39420937 |
Overall safety findings
What studies said about safety as a whole, without naming a specific effect.
| Finding | How common | Study type | Source |
|---|---|---|---|
| Discontinuation due to adverse reactions | 8% overall (6%, 9%, 10% by dose) vs 3% placebo | FDA label | FDA label (Foundayo) |
| Discontinuation due to adverse events | 6·1-9·9% vs 4·1% placebo | Human RCTn = 1613 | Lancet 2026, PMID 41275875 |
| Discontinuation due to adverse events | 5.3 to 10.3% vs 2.7% placebo | Human RCTn = 3127 | The New England journal of medicine 2025, PMID 40960239 |
| Discontinuation due to adverse events | 4.4 to 7.8% vs 1.4% placebo | Human RCTn = 559 | The New England journal of medicine 2025, PMID 40544435 |
What users report
Side effects people describe from their own use of Orforglipron, quoted from 8 Reddit threads we read in r/Retatrutide, r/moreplatesmoredates and r/tirzepatidecompound (searched 11 Oct 2026). Each count is the number of different people in those threads, not how common the effect is. These reports are unverified: products bought outside a pharmacy are often mislabelled or impure, and many people take several compounds at once.
Nobody in these threads described a specific side effect from Orforglipron. That is a small sample, not evidence that it is safe.
A symptom others mention is not proof that it is harmless. If you have anything on the urgent list below, get care whatever others report.
What is not known
- How common each effect is at the doses people use outside of studies.
- Effects that take longer to appear than the length of the published studies.
- How Orforglipron interacts with other medicines and supplements.
- Whether research-grade products, which are not checked by the FDA, behave like the material used in studies.
When to get medical help
This is not a complete list. A doctor or pharmacist can help you judge whether a symptom is related.
Discontinuations: label versus trials
The Foundayo label pools two trials and reports permanent stops by dose.[1]
In the ATTAIN-1 obesity trial, adverse events led to discontinuation in 5.3 to 10.3% of patients in the orforglipron groups and 2.7% on placebo.[7]
In the early type 2 diabetes trial, permanent discontinuation due to adverse events occurred in 4.4 to 7.8% on orforglipron and 1.4% on placebo.[8]
In the phase 2 obesity trial, gastrointestinal events led to discontinuation of orforglipron in 10 to 17% of participants across dose cohorts.[9]
Excess over placebo in percentage points: label pool 5 overall (3 at 5.5 mg, 6 at 9 mg, 7 at 17.2 mg); ATTAIN-1 range 2.6 to 7.6; early type 2 diabetes trial range 3.0 to 6.4.
Calculated from label 8, 6, 9, 10; label placebo 3; attain1 5.3, 10.3; attain1 placebo 2.7; t2d 4.4, 7.8; t2d placebo 1.4. Formula: orforglipron % minus placebo %
What the Foundayo label flags
The Foundayo label contraindicates use in people with a personal or family history of medullary thyroid carcinoma or with MEN 2.[1]
The label says the human relevance of the GLP-1 receptor-dependent thyroid C-cell tumors seen in rodents has not been determined for orforglipron.[1]
The label reports tachycardia in 3% of Foundayo-treated patients and 0.9% of those on placebo.[1]
In the pooled trials, the label reports cholelithiasis in 1% on Foundayo and 0.7% on placebo, and acute cholecystitis in 0.4% and 0.3%.[1]
Pregnancy and contraception
The label says to discontinue Foundayo when pregnancy is recognized.[1]
For oral hormonal contraceptives, the label advises switching to a non-oral method or adding a barrier method for 30 days after initiation and after each dose escalation.[1]
Common questions
What are the side effects of orforglipron?
The Foundayo label lists as most common (reported in at least 5% of treated patients) nausea, constipation, diarrhea, vomiting, dyspepsia, abdominal pain, headache, abdominal distension, fatigue, eructation, gastroesophageal reflux disease, flatulence and hair loss.[1]
What side effects do people who use Orforglipron report?
In the 8 Reddit threads we read (11 Oct 2026), nobody described a specific side effect from Orforglipron. That is a small sample, not evidence of safety.
Is Orforglipron safe?
Orforglipron has an FDA-approved label that lists its known risks. That label covers the approved product used as prescribed, not compounded or research-chemical versions.
Does orforglipron interact with other medicines?
The label's contraceptive advice covers 30 days after starting and after each dose escalation.[1]
How does orforglipron compare with oral semaglutide on stomach side effects?
In a head-to-head trial, gastrointestinal events occurred in 59% and 58% on orforglipron versus 37% and 45% on oral semaglutide.[3]
What are the contraindications for orforglipron?
The label contraindicates orforglipron with a personal or family history of medullary thyroid carcinoma or MEN 2, and with known serious hypersensitivity to orforglipron or its excipients.[1]
How long do orforglipron's stomach side effects last?
The label says nausea, vomiting and diarrhea were more frequent while the dose was being raised and became less frequent over time; it gives no day count.[1]
How severe were orforglipron's gastrointestinal reactions on the label?
Of patients who reported gastrointestinal reactions, 60% called them mild, 36% moderate and 4% severe.[1]
Does orforglipron cause pancreatitis?
In the pooled label trials, 6 adjudicated acute pancreatitis events occurred in 6 Foundayo-treated patients (0.14 per 100 years of exposure) versus 2 events in 1 placebo patient (0.04).[1]
How do I report a side effect from orforglipron (Foundayo)?
The label tells people to report suspected adverse reactions to Eli Lilly at 1-800-LillyRx (1-800-545-5979) or to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch; the full prescribing information is the DailyMed label cited on this page.[1]
More on Orforglipron
Sources
- 1These highlights do not include all the information needed to use FOUNDAYO safely and effectively. See full prescribing information for FOUNDAYO. FOUNDAYO (orforglipron) tablets, for oral use Initial FDA label (Foundayo), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 2Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.Lancet (London, England) · 2026PMID 41275875Accessed 2 Oct 2026
- 3Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial.Lancet (London, England) · 2026PMID 41765029Accessed 2 Oct 2026
- 4Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial.Lancet (London, England) · 2026PMID 42259339Accessed 2 Oct 2026
- 5Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial.Nature medicine · 2026PMID 42120723Accessed 2 Oct 2026
- 6Orforglipron for obesity treatment in older patients ≥65 years with or without type 2 diabetes: A post hoc subgroup analysis of the ATTAIN-1 and ATTAIN-2 trials.Obesity pillars · 2026PMID 42577069Accessed 2 Oct 2026
- 7Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.The New England journal of medicine · 2025PMID 40960239Accessed 2 Oct 2026
- 8Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes.The New England journal of medicine · 2025PMID 40544435Accessed 2 Oct 2026
- 9Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.The New England journal of medicine · 2023PMID 37351564Accessed 2 Oct 2026
- 10Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study.Lancet (London, England) · 2023PMID 37369232Accessed 2 Oct 2026
- 11Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants.Diabetes, obesity & metabolism · 2023PMID 37344954Accessed 2 Oct 2026
- 12Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes.Diabetes, obesity & metabolism · 2023PMID 37264711Accessed 2 Oct 2026
- 13Effects of once-daily oral orforglipron on weight and metabolic markers: a systematic review and meta-analysis of randomized controlled trials.Archives of endocrinology and metabolism · 2024PMID 39420937Accessed 2 Oct 2026
Found an error? Report a correction.